Key Spec Table
|Empirical Formula||CAS #|
Pricing & Availability
An invalid quantity was specified. The product quantity has been adjusted.
|US1171263-5MG||Glass bottle||5 mg||
|Overview||A cell-permeable 4-hydroxy-2-oxo quinoline carboxamide that acts as an agonist of AMPK signaling. It is shown to reduce fat storage in C. elegans (EC50 ~ 0.1 µM) and reduce the expression level of fat-7 (a C. elegans ortholog of mammalian stearoyl-CoA desaturase-1), through aak-1 (an ortholog for the AMPK-α1 catalytic subunit) and K08F8.2 (a transcription factor) dependent mechanisms. In addition, it markedly reduces the number of lipid droplets in HepG2 human hepatocarcinoma cells at 25 µM, and elicits the phosphorylation and inactivation of acetyl coenzyme A carboxylase (ACC, the enzyme that catalyzes the rate-limiting step in de novo fatty acid synthesis). F17-induced ACC phosphorylation can be abrogated by simultaneous treatment with an AMPK inhibitor compound C (Cat. No. 171260).|
|References||Lemieux, G.A., et al. 2011. Nat. Chem. Biol. 7, 206.|
|Application||The AMPK Signaling Agonist, F17, also referenced under CAS 280112-24-5, controls the biological activity of AMPK. This AMPK activator and small molecule/inhibitor is primarily used for Biochemicals applications.|
|Purity||≥95% by HPLC|
|Safety Information according to GHS|
|Product Usage Statements|
|Packaged under inert gas||Packaged under inert gas|
|Lemieux, G.A., et al. 2011. Nat. Chem. Biol. 7, 206.|
Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.